Retinoids for treatment of Alzheimer's disease

Retinoids are Vitamin A derivatives involved in cellular regulatory processes including cell differentiation, neurite outgrowth and defense against oxidative stress. Retinoids may also influence Amyloid beta processing upregulation of alpha secretase via ADAM10. Vitamin A and other retinoids also directly inhibit formation of Amyloid fibrils in vivo. These properties of retinoids are relevant to theories of Alzheimer's disease pathogenesis. Retinoids are already used in treatment of acne vulgaris, psoriasis, neuroblastoma and acute promyelocytic leukemia. Clinical studies involving in cognitively impaired older adults with Alzheimer's disease are beginning with a variety of retinoids. These studies need to address safety issues of retinoids in older populations, and hold hope for demonstrating efficacy in translating these basic mechanisms to treatment of a widespread dementing illness.

[1]  C. Jack,et al.  Chronic divalproex sodium use and brain atrophy in Alzheimer disease , 2011, Neurology.

[2]  D. Selkoe,et al.  Resolving controversies on the path to Alzheimer's therapeutics , 2011, Nature Medicine.

[3]  M. Sano,et al.  A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease , 2011, Neurology.

[4]  Xiongwei Zhu,et al.  Cell cycle deregulation in the neurons of Alzheimer's disease. , 2011, Results and problems in cell differentiation.

[5]  A. Takashima,et al.  Vitamin A has anti-oligomerization effects on amyloid-β in vitro. , 2011, Journal of Alzheimer's disease : JAD.

[6]  Karl Herrup,et al.  DNA damage and cell cycle events implicate cerebellar dentate nucleus neurons as targets of Alzheimer's disease , 2010, Molecular Neurodegeneration.

[7]  G. Wolf.  Tissue-specific increases in endogenous all-trans retinoic acid: possible contributing factor in ethanol toxicity. , 2010, Nutrition reviews.

[8]  F. Fahrenholz,et al.  Retinoids as a Perspective in Treatment of Alzheimer’s Disease , 2010, Neurodegenerative Diseases.

[9]  H. T. Kang,et al.  Reciprocal roles of SIRT1 and SKIP in the regulation of RAR activity: implication in the retinoic acid-induced neuronal differentiation of P19 cells , 2009, Nucleic acids research.

[10]  Robert C Green,et al.  Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. , 2009, JAMA.

[11]  Hyoung-Gon Lee,et al.  All-trans retinoic acid as a novel therapeutic strategy for Alzheimer’s disease , 2009, Expert review of neurotherapeutics.

[12]  M. Staufenbiel,et al.  Oral administration of synthetic retinoid Am80 (Tamibarotene) decreases brain beta-amyloid peptides in APP23 mice. , 2009, Biological & pharmaceutical bulletin.

[13]  F. Fahrenholz,et al.  Up‐regulation of the α‐secretase ADAM10 by retinoic acid receptors and acitretin , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  K. Shudo,et al.  Towards Retinoid Therapy for Alzheimer’s Disease , 2009, Current Alzheimer research.

[15]  M. Block,et al.  Retinoic Acid Attenuates β-Amyloid Deposition and Rescues Memory Deficits in an Alzheimer's Disease Transgenic Mouse Model , 2008, The Journal of Neuroscience.

[16]  D. Thompson,et al.  Retinoic acid syndrome: a review , 2008, Journal of clinical pharmacy and therapeutics.

[17]  G. Wolf.  Retinoic acid as cause of cell proliferation or cell growth inhibition depending on activation of one of two different nuclear receptors. , 2008, Nutrition reviews.

[18]  K. Matthay,et al.  A phase 2 trial of all‐trans‐retinoic acid in combination with interferon‐α2a in children with recurrent neuroblastoma or Wilms tumor: A Pediatric Oncology Branch, NCI and Children's Oncology Group Study , 2007 .

[19]  A. Goodman.  Retinoid receptors, transporters, and metabolizers as therapeutic targets in late onset Alzheimer disease , 2006, Journal of cellular physiology.

[20]  S. Tanumihardjo,et al.  The acute and chronic toxic effects of vitamin A. , 2006, The American journal of clinical nutrition.

[21]  F. Fahrenholz,et al.  Shedding of the amyloid precursor protein‐like protein APLP2 by disintegrin‐metalloproteinases , 2005, The FEBS journal.

[22]  F. Fahrenholz,et al.  Genomic structure and functional characterization of the human ADAM10 promoter , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  A. Takashima,et al.  Vitamin A exhibits potent antiamyloidogenic and fibril-destabilizing effects in vitro , 2004, Experimental Neurology.

[24]  B. Borroni,et al.  Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines , 2004, Journal of neurochemistry.

[25]  P. So,et al.  Disruption of the retinoid signalling pathway causes a deposition of amyloid β in the adult rat brain , 2004, The European journal of neuroscience.

[26]  L. Horrocks,et al.  Retinoic acid-mediated phospholipase A2 signaling in the nucleus , 2004, Brain Research Reviews.

[27]  J. Malter,et al.  Anti‐Aβ: The good, the bad, and the unforeseen , 2004 .

[28]  R. Larson,et al.  Retinoic acid syndrome: manifestations, pathogenesis, and treatment. , 2003, Best practice & research. Clinical haematology.

[29]  R. Donato,et al.  Intracellular and extracellular roles of S100 proteins , 2003, Microscopy research and technique.

[30]  L. Schneider,et al.  A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. , 2003, Current drug targets.

[31]  A. Gural,et al.  Extensive Splenic Infarction, Deep Vein Thrombosis and Pulmonary Emboli Complicating Induction Therapy with All-trans-retinoic Acid (ATRA) for Acute Promyelocytic Leukemia , 2003, Leukemia & lymphoma.

[32]  P. Vallance,et al.  all-trans-Retinoic Acid Increases Nitric Oxide Synthesis by Endothelial Cells: A Role for the Induction of Dimethylarginine Dimethylaminohydrolase , 2002, Circulation research.

[33]  K. Herrup,et al.  Re-expression of cell cycle proteins induces neuronal cell death during Alzheimer's disease. , 2002, Journal of Alzheimer's disease : JAD.

[34]  E. Melamed,et al.  Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier , 2001, Neuropharmacology.

[35]  C. Orfanos,et al.  [Trans-acitretin is metabolized back to etretinate. Importance for oral retinoid therapy]. , 1996, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[36]  K. Weismann,et al.  Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. , 1993, The Journal of investigative dermatology.

[37]  D. Marshak,et al.  Increased S100β neurotrophic activity in Alzheimer's disease temporal lobe , 1992, Neurobiology of Aging.